In the pharmaceutical market of Ukraine presented the resulting genetically engineered newest recombinant probiotic Subalin for the dysbiotic violations correction and normal flora of the intestine restore with subsequent normalization of digestion, intestinal motility and detoxification in the complex treatment of patients with the syndrome of intestinal infections endotoxemia, acute and chronic viral hepatitis A and hepatitis B and patients carrying HBsAg, patients with bacterial and viral and bacterial meningoencephalitis, for the adult and pediatric patients with contraindications to the antibiotics therapy.
This biological product is created by Ukrainian scientists (V.V. Smirnov, S.R. Reznik, I.B. Sorokulova et al., Institute of Microbiology and Virology of Ukrainian Academy of Sciences, Research and Design Technological Institute of Biologically Active Substances, Research and Production Association «Vector») on the basis of the strain Bifidobacterium subtilis VKPM B-4759, containing the recombinant plasmid with the gene of human α2-interferon.
Subalin shows polytropic antibacterial, antidiarrheal, immunomodulatory, antiviral, antitumor therapeutic and preventive action in the combined therapy of the adults and children, characterized by a high antagonistic activity against a broad spectrum of pathogenic and opportunistic microorganisms (Salmonella, Staphylococcus, Pseudomonas aeruginosa, Proteus, Klebsiella, Candida), antiviral activity (due to synthesis of α2- and U-interferon and the ability of when administered orally to induce the synthesis of g-interferon).
This microbial strain was deposited in the Collection of Industrial Microorganisms, adapted to the long-term persistence in the human intestine and adapted to the human population living in Ukraine. Russian Patent RU2035185. Subalin has no analogues in the world of medical practice. Subalin® (Ukraine, Kiev, Biopharma Company) is available as a dry powder in vials number 10 for the preparation of oral suspension (1 dose contains 1∙109 live microbial cells Bacillus subtilis UKMV-5020) at an average retail price of around 88–95 UAH (8-9 EUR) per pack.
Polytropic probiotic action, low toxicity, clinically proven efficacy and pharmacoeconomic availability make Subalin as popular and promising modern probiotics drug. These properties of the Subalin increase the clinicians empowers individualized approach to the treatment of dysbiosis in adult and pediatric practice with the most rational use of recombinant preparations of microbial origin.
The work is submitted to the International Scientific Conference «Homeostasis and infectious process», Israel (tel Aviv), February, 20–27, 2014, came to the editorial office оn 03.02.2014.